DIALOG-SEMICONDUCTOR-PLC
12.12.2017 08:15:12 CET | Business Wire | Press release
Dialog Semiconductor plc (XETRA: DLG ), a provider of highly integrated power management, AC/DC power conversion, and low power connectivity technology, today announced that Dialog's RapidCharge(TM) chipset enabling the SuperCharge protocol was selected for the new HUAWEI Mate 10, HUAWEI Mate 10 Pro and Porsche Design HUAWEI Mate 10 smartphone adapters. As fast charging smartphone adoption accelerates, this represents another significant milestone in the company's AC/DC power conversion leadership as Dialog continues to maintain a market share above 60%.
HUAWEI recently launched their impressive Mate 10 series with breakthrough AI devices that combine innovative hardware and software. The Kirin 970 chipset and EMUI 8.0 is the world's first AI processor for smartphones with a dedicated Neural Network Processing Unit (NPU). All HUAWEI Mate 10 series sport the New Leica Dual Camera with SUMMILUX-H lenses, with both featuring an aperture of f/1.6, and intelligent photography including AI-powered Real-Time Scene and Object Recognition and AI-powered Bokeh Effect.
With an all-new HUAWEI FullView Display, the HUAWEI Mate 10 features a stunning 5.9-inch screen with a 16:9 display, barely-there-bezel and HDR10 to support vivid colors. The 6-inch HUAWEI Mate 10 Pro features an 18:9 OLED display, high screen-to-body ratio and HDR10 for dynamic video viewing. The HUAWEI Mate 10 series pack a 4000 mAh high-density battery featuring a smart battery management system that understands user behavior and intelligently allocates resources to maximize battery life. It also supports 4.5 V / 5 A low-voltage HUAWEI SuperCharge technology, powering the device from one percent to 58 percent in 30 minutes.(1) Additionally, HUAWEI SuperCharge is the world's first fast charging technology to receive TÜV Fast-Charge Safety Certification, ensuring safe end-to-end charging.
"Our chipset gives consumers the chance to do away with lengthy charge times, taking smartphone charging speed to unprecedented levels, without compromising safety," said Davin Lee, Senior Vice President and General Manager, Power Conversion Business Group, Dialog Semiconductor. "We are extremely pleased to have been chosen by Huawei for their flagship HUAWEI Mate 10 and HUAWEI Mate 10 Pro phone adapters."
Dialog's iW631 RapidCharge interface IC resides on the secondary side of the AC/DC charger power supply and works with the iW1780H PrimAccurate(TM) primary-side digital AC/DC power supply controller. The iW1780H uses a unique secondary-to-primary digital communication link signal and built-in decoder to receive all rapid charge commands and then dynamically scales the output voltage regulation and output current limit of the adapter to deliver the required power. This approach eliminates discrete components, reduces cost and significantly simplifies charger designs. Current sensing is performed by the iW1780H on the primary side, eliminating the need for a secondary-side current sense resistor for an inherently high efficiency solution.
The iW671 synchronous rectifier further boosts the efficiency close to 90%, facilitating the high power density required for the small form adapters. The chipset (iW631, iW1780H & iW671 ) provides significant protection features for the smartphone's charging system, including Dialog's proprietary SmartDefender(TM) advanced hiccup technology that addresses soft short circuits, helping to prevent excessive heat build-up and damage to charger cables and connectors for safer, more reliable rapid charging. Additionally, automatic AC un-plug detection protects the smartphone battery from high voltage damage if the charger is unplugged, then re-plugged in to the mains with the charging cable still connected.
NOTES
(1) Based on Huawei laboratory testing results. In the test, the device was charged from 1 percent battery with the display off, through the HUAWEI SuperCharge charger and cable, in an environment with a 4G network, 25 C temperature, and relative humidity of 45-80 percent.
Dialog, the Dialog logo, Prim Accurate, SmartDefender and RapidCharge are trademarks of Dialog Semiconductor plc or its subsidiaries. All other product or service names are the property of their respective owners. (c) Copyright Dialog Semiconductor 2017. All rights reserved.
About Dialog Semiconductor
Dialog Semiconductor is a leading provider of integrated circuits (ICs) that power mobile devices and the Internet of Things. Dialog solutions are integral to some of today's leading mobile devices and the enabling element for increasing performance and productivity on the go. From making smartphones more power efficient and shortening charging times, enabling home appliances to be controlled from anywhere, to connecting the next generation of wearable devices, Dialog's decades of experience and world-class innovation help manufacturers get to what's next.
Dialog operates a fabless business model and is a socially responsible employer pursuing many programs to benefit the employees, community, other stakeholders and the environment we operate in. Dialog Semiconductor plc is headquartered in London with a global sales, R&D and marketing organization. In 2016, it had approximately $1.198 billion in revenue and was one of the fastest growing European public semiconductor companies. It currently has approximately 2,050 employees worldwide. The company is listed on the Frankfurt (FWB: DLG) stock exchange (Regulated Market, Prime Standard, ISIN GB0059822006) and is a member of the German TecDax index.
For more information, visit www.dialog-semiconductor.com .
| Language: | English | |
| Company: | Dialog Semiconductor Plc. | |
| Tower Bridge House, St. Katharine's Way | ||
| E1W 1AA London | ||
| United Kingdom | ||
| Phone: | +49 7021 805-412 | |
| Fax: | +49 7021 805-200 | |
| E-mail: | ||
| Internet: | ||
| ISIN: | GB0059822006 | |
| WKN: | 927200 | |
| Indices: | TecDAX | |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: http://www.businesswire.com/news/home/20171211006374/en/
Contact:
Dialog Semiconductor
Lauren Ofstedahl, +1-408-845-8518
lauren.ofstedahl@diasemi.com
www.dialog-semiconductor.com
Twitter:
@DialogSemi
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom